Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | DHPS | P49366 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25425449 | 0.75 | EGLN1 (0.53) | EGLN1MAPK14DHPS | |
| SCHEMBL12502567 | 0.73 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL4147543 | 0.73 | PARP1 (0.62) | EGLN1MAPK14DHPS | |
| SCHEMBL12502415 | 0.73 | EGLN1 (1.00) | EGLN1 | |
| SCHEMBL15610873 | 0.72 | EGLN1 (0.68) | EGLN1 | |
| SCHEMBL18043936 | 0.71 | EGLN1 (0.70) | EGLN1 | |
| Formamide SCHEMBL27938877 | 0.71 | EGLN1 (0.89) | EGLN1 | |
| SCHEMBL24499451 | 0.70 | HTR6 (0.54) | EGLN1MAPK14DHPS | |
| SCHEMBL25427033 | 0.70 | EGLN1 (0.53) | EGLN1MAPK14DHPS | |
| SCHEMBL30381356 | 0.70 | EGLN1 (0.53) | EGLN1MAPK14DHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | EGLN1 3836/4885MAPK14 414/4885DHPS 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.